ABSTRACT. With-no-lysine (K) kinase-4 (WNK4) is a newly cloned kinase-encoding gene that plays a crucial role in the maintenance of electrolyte homeostasis. Mutations of WNK4 can cause pseudohypoaldosteronism type α, an autosomal dominant disease characterized by hyperkalemia, metabolic acidosis and hypertension. We explored the expression and regulatory mechanism of WNK4 in the human kidneys, which is a key regulator of blood pressure. Expression of WNK4 was determined by RT-PCR. Transcription initiation site and regulatory elements in the promoter region of WNK4 were systematically analyzed with a combined set of experimental and bioinformatic methods. Using 5'-RACE, we have determined the transcription initiation site. We identified a number of putative cis-acting elements by analysis of the promoter region with the TRANSFAC-TESS software; these were sub- Regulation of WNK4 expression in the kidneys sequently confirmed with an electrophoresis mobility shift assay. As confirmed by a CAT-ELISA reporter assay, the promoter region of WNK4 has a high level of transcriptional activity. Several hormones, in particular dexamethasone, can suppress the level of WNK4 mRNA. These results have shed light on the regulatory mechanism of WNK4 expression in kidneys, as well as the influence of various hormones on expression levels. This should prove useful for studies on the roles of WNK4 in the pathogenesis of hypertension.
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INTRODUCTION
With-no-lysine (K) kinase-4 (WNK4) is a newly cloned serine/threonine kinase gene. Mutations of its exons 7 and 17 can cause pseudohypoaldosteronism type α, an autosomal dominant disease featuring hyperkalemia, metabolic acidosis, and hypertension. Expression of WNK4 has been found in several types of chloride-transporting epithelia, with its protein products located subcellularly near the tight junctions, along the lateral membranes, and within the cytoplasm. Previous studies indicated that WNK4 can suppress the activities of NaCl co-transporter and potassium channels in the outer layer of renal medulla while enhance paracellular chloride flux (Kahle et al., 2003 (Kahle et al., , 2004 Yamauchi et al., 2004) . Therefore, the WNK4 gene probably plays a crucial role in blood pressure regulation. Of note, Erlich et al. (2003) also found that single nucleotide polymorphisms in the WNK4 gene can influence the risk of hypertension in Caucasians. Our previous study suggested a similar role for the gene in Chinese hypertensive patients (Sun et al., 2003) .
To date, most studies on the WNK4 gene have focused on its functions, while the regulatory mechanisms of its expression remained poorly understood. The present study therefore aimed to explore the mechanisms of transcriptional modulation of WNK4. To explore whether WNK4 also plays a role in hormone-influenced blood pressure modulation, we have also investigated the influence of various hormones on its transcription.
MATERIAL AND METHODS

Tissue samples and cell culture
With informed consent obtained, tissue samples were obtained from non-viable fetuses from the Shengjing Hospital Affiliated to China Medical University. Human embryo kidney 293 (HEK293) cells were cultured in a minimum essential medium (Gibco, Los Angeles, CA, USA) supplemented with 15% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin at 37°C in a humidified atmosphere containing 5% CO 2 .
RNA preparation and RT-PCR
Total RNA was isolated with the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized with reverse transcription using random primers following a protocol recommended by the manufacturer (Promega, Madison, WI, USA). PCR was carried out under optimized conditions using the following primers, with β-actin used as an internal control: WNK4 primer sense: 5'-GTTCATTCTGCCTTCGGAGCG-3' and antisense: 5'-CAGTCATCA CAGCCAGTGAGA-3'; β-actin primers sense: 5'-AGAGCTACGAGCTGCCTGAC-3' and antisense: 5'-AGTACTTGCGCTCAGGAGGA-3'.
5'-Rapid amplification of cDNA (5'-RACE) and software analysis
A human kidney Marathon-Ready cDNA amplification kit (Clontech, Mountain View, CA, USA) was used following manufacturer instructions. The forward primers included a 27-mer adaptor primer (AP1) and a 23-mer nested AP2. The reverse primers were gene-specific primers (GSP) for the exon 1 of the WNK4 gene, which included an outer primer (GSP1, 5'-ACGCGCGGAGTCTTCCGCAGCCT-3') and an inner primer (GSP2, 5'-CTGGGACATG AGGACGGTGGTCT-3'). The first round of PCR was carried out with the Marathon-Ready cDNA as the template and AP1 and GSP1 as primers. The product was diluted and used as the template for a second round PCR with AP2 and GSP2 as primers. The PCR product was analyzed by agarose gel electrophoresis. Subsequently, DNA from the major band was cloned into a pMD18-T vector and sequenced. On the basis of the 5'-RACE results, the transcription initiation site and promoter region of WNK4 were determined.
Electrophoresis mobility shift assay (EMSA)
Nuclear extract from kidney tissues was prepared following standard procedures. To prepare the probe, an oligonucleotide 5'-CGCGGCTGGGCGGGGCGGTGACTAAGGT-3' containing the potential Sp1 and AP1 elements was synthesized, annealed with a complementary fragment, and labeled with [γ-
32 P]-ATP (Furui Biotechnology, Beijing, China). The binding reaction was performed in a volume of 15 μL containing approximately 5000 cpm of labeled probe and 5 μg nuclear extract. After incubating on ice for 1 h, the reaction mixtures were loaded onto an 8% polyacrylamide gel and run at 150 V for 4 h. Subsequently, the gels were dried under vacuum and analyzed with autoradiography.
Plasmid construction
A 1275-bp fragment harboring the WNK4 promoter was obtained through PCR using human genomic DNA as the template and 5'-CACTGACCTCTCCGTTCGGC-3' (forward) and 5'-CAGATCATTCAGGGCAAAGAC-3' (reverse) as primers. The PCR product was cloned into a pDM18-T vector, and subcloned into a unique Hindβ/XbaI site of a pCATBasic vector (Promega) in order to generate a reporter construct (pCAT-WNK4-promoter). The construct was confirmed with sequencing. Coding frame shift of the CAT gene was excluded. For transient transfection, the plasmids were prepared using an Axyprep Plasmid Miniprep kit (Axygen Biosciences, Union City, CA, USA).
Transient transfection and ELISA
HEK293 cells were seeded on 6-well plates and grown to 80-90% confluence. For
Regulation of WNK4 expression in the kidneys transient transfection, the standard medium was replaced with a serum-free medium. To normalize transfection efficiencies, pSV-β-galactosidase (Promega) was used as the internal control. In each experiment, 0.5 μg pCAT-WNK4-promoter construct and 0.05 μg pSV-β-galactosidase vector were co-transfected into cultured cells using Lipofectamine 2000 (Invitrogen) transfection reagents. Activities were determined from a single sample using a CAT-ELISA kit (Roche, Mannheim, Germany) according to manufacturer instructions.
Northern blotting
Thirty micrograms of total RNA was fractionated by electrophoresis on a 1% agaroseformaldehyde gel, blotted by capillary transfer onto a nylon membrane (Amersham Biosciences, Sweden), and cross-linked through UV irradiation. The membrane was probed with an antisense cRNA from WNK4 cDNA labeled by random priming using a commercial kit (Amersham Biosciences) and [
32 P]-dCTP. The blot was pre-hybridized at 42°C for 2 h in 50% formamide, 0.1% SDS, 2X Denhardt's solution, 5X standard SSPE, and 0.1 mg/mL salmon sperm DNA. Subsequently, probe was added to the pre-hybridization solution, and the blot was hybridized overnight at 42°C, washed twice for 10 min each at 55°C in 2X standard saline citrate and 0.1% SDS, and autoradiographed through an intensifying screen at -70°C. The WNK4 probe was then removed with boiling, and the same blot was re-hybridized to a cDNA probe encoding for β-actin.
RESULTS
Expression of the WNK4 gene in various tissues
To assess expression of the WNK4 gene, total RNA from fetal kidney, heart, brain, small intestine, spleen, liver, and lung was extracted and assayed with RT-PCR. As shown, WNK4 was expressed in all of the samples except liver. The most prominent expression was found in the kidneys (Figure 1) . 
Identification of the WNK4 transcription initiation site
5'-RACE was performed in order to identify the transcription initiation site of the WNK4 gene. For the first round of PCR, a primer binding with the first exon and human kidney Marathon-Ready cDNA were used, and a 442-bp band was derived. With diluted PCR product as the template, a 102-bp band was obtained with 5'-nested RACE (Figure 2) . DNA from the 2 bands was then cloned into a pMD18-T vector and sequenced. BLAST analysis of the 2 sequences indicated a same transcription initiation site. 
Functional analysis of the WNK4 promoter
By analyzing a 1000-bp sequence upstream of the WNK4 transcription initiation site with the TRANSFAC-TESS software, a number of cis-acting elements, including AP1, AP2, Sp1, and GRE, were discovered (part of the results are shown in Figure 3A) , which confirmed the region to be the promoter of the WNK4 gene.
An EMSA assay was performed to verify the results of the above prediction. Nucleotides (named SA) containing the potential Sp1 and AP1 elements (Figure 4 ) were synthesized and labeled as probe. As demonstrated by EMSA, nuclear extract from kidney tissues could form specific complexes with the SA probe, and this can be competed by a cold SA sequence, which confirmed that sequence from the WNK4 promoter can bind specifically with transcription factors Sp1 and AP1 ( Figure 3B ). 
Reporter assay for the WNK4 promoter
To explore the activity of the WNK4 promoter, a pCAT-WNK4-promoter plasmid was constructed and transiently transfected into HEK293 cells. Using β-gal as the internal control, ELISA was carried out to detect the promoter activities. As shown in Figure 4 , compared with pCAT-Basic, the pCAT-WNK4-promoter showed a high activity, which confirmed a transactivation function of the WNK4 promoter.
Influence of various hormones on WNK4 expression
To assess the influence of various hormones on the expression of WNK4 in the kidney, HEK293 cells were treated respectively with 5 M angiotensin α, 1 μM estrogen, 1 nM dexamethasone, 100 nM insulin, and 6 nM growth hormone. The results of RT-PCR are shown in Figure 5A . Compared with untreated controls, all of the above hormones suppressed the expression of WNK4, and among these, the effect of dexamethasone was the most pronounced. Northern blotting analysis also confirmed suppression of WNK4 gene expression by these hormones ( Figure 5B ). 
Dexamethasone regulation of WNK4 promoter activity
To assess the effect of particular hormones on WNK4 transcription, CAT-ELISA was carried out after co-transfection of pCAT-WNK4-promoter and pSV-β-galactosidase into the HEK293 cells. As shown in Figure 6 , under basal conditions, addition of dexamethasone suppressed the activity of the WNK4 promoter in a dose-dependent manner, with the lower concentration of dexamethasone (1 nM) showing a more prominent effect than the higher one (10 nM).
DISCUSSION
In the present study, we explored tissue-specific expression of the WNK4 gene and found an abundant expression in the kidney. The WNK4 protein has been shown to regulate trans-and paracellular ion flux across diverse epithelia. Regulation of WNK4 expression may therefore be crucial for the maintenance of electrolyte homeostasis. The wide range of WNK4 expression, as discovered here, seems to suggest a role for the gene in ion transportation regulation. Considering its abundant expression in the kidneys, we utilized kidney tissues to explore the regulation mechanism of WNK4 transcription. Using a 5'-RACE assay, we determined the transcription initiation site. With a number of transcription factor binding sites from the promoter region predicted, EMSA assay confirmed that at least the AP1 and Sp1 elements are functional. CAT-ELISA assay also confirmed a strong transcription activity for the promoter region.
Similar to other kinases, WNK4 is a critical signal-regulating enzyme. When activated by upstream signals, protein kinases can up-or downregulate the activities of downstream proteins and participate in various cell activities. Of note, many of such processes are modulated by hormones and cytokines (Dhanasekaran, 1998; Dhanasekaran and Premkumar Reddy, 1998; Mader et al., 1993) . For example, as a signal molecule, a steroid hormone may enter the nucleus and bind with a cis-acting element to regulate gene expression. Previous studies suggested that several hormones, including estrogen and growth hormone, may participate in the regulation of blood pressure (Bielohuby et al., 2009; Vongpatanasin, 2009 ). Furthermore, a putative glucocorticoid response element has been identified in the WNK4 promoter. As confirmed by our study, estrogen, insulin, dexamethasone, angiotensin II, and growth hormone can all suppress the expression of WNK4, with dexamethasone showing the most prominent effect and in a concentration-dependent manner. The stronger effect of the lower concentration may have been due to a negative feedback mechanism. Our study has confirmed the wide range of tissue expression of WNK4 and delineated the regulatory mechanism of its transcription. It is likely that various hormones can influence blood pressure by modulating WNK4 expression. The above results may provide a basis for further delineation of the role of WNK4 in the regulation of blood pressure.
